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ABSTRACT 
Background: Ablation of the synovium with radiopharmaceuticals, referred to as 
radiation synovectomy, (RS), has emerged as a simple affordable and safe procedure that 
is highly effective in preventing chronic disabling end stage arthritis in haemophilia 
patients. 
Objective: To provide a review of the principles and role of radiation synovectomy, (RS), 
in the management of haemophiliac patients with chronic haemarthrosis, and to consider 
the possibility of this treatment option in Kenyan patients with haemophilia. 
Data sources: A literature search through the internet using Boolean commands, 
PubMed interface to MEDLINE, Evidence, the Cochrane library. Papers from reputable 
haematology and radiation medicine journals, as well as conference presentations of 
the World Federation of Hemophilia were also included. 
Data selection: The searches for papers, abstracts and reviews were limited to English 
language, haemophilia, haemarthrosis, synovectomy, RS, radiopharmaceuticals for 
RS and safety of RS. 
Data extraction: All abstracts, and most of the papers were reviewed. Only those 
abstracts, papers and conference materials from reputable sources were used for this 
paper. 
Data synthesis: All available papers and abstracts were reviewed for the most up to 
date information. The indications, requirements, procedure and safety aspects of RS 
were examined. The merits of alternative forms of synovectomy were considered. In 
the light of this information, the feasibility of RS as a treatment option for haemophilia 
patients in Kenya was considered. 
Conclusion: Radiation synovectomy has been carried out on thousands of haemophilia 
patients with chronic haemathrosis over the last 20 years. Experience accumulated in 
numerous centres in America, Europe, Asia, North and South Africa indicates that 
majority of haemophilia patients undergoing RS are spared life long crippling arthritis 
and deformity. The principle safety concern of the potential for late radiation- related 
malignancy has been mitigated by appropriate choice of radiopharmaceuticals, and 
carefully executed procedure. The effectiveness, simplicity and affordability of RS 
make it particularly suitable for treatment of haemophilia patients in developing 
countries like Kenya. 
INTRODUCTION 
Haemarthrosis is the most painful and the most 
physically and psychologically debilitating 
manifestation of severe haemophilia (1). Frequently 
affected joints are the knees, ankle joints, elbows and the 
shoulders in that order. Bleeding usually commences 
in early childhood (2). Repeated haemarthrosis 
eventually leads to hypertrophy of the synovium and 
chronic synovitis (3). The inflammed hypertrophied 
and highly vascular synovium is prone to frequent 
haemorrhages, leading to chronic haemarthrosis. 
A chronic self-perpetuating cycle of haemarthrosis-
synovitis-haemarthroses is established in the target 
joint (4). Normally the breakdown products of blood, 
including iron, are removed by the synovium. In 
chronic synovitis the synovium is overwhelmed and 
the breakdown products lead to destruction of the 
articular cartilage and irreversible degeration and 
destruction of the bone (5,6). 
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  The ideal way to prevent chronic synovitis is 
by prophylactic administration of clotting factors to 
prevent bleeds, beginning in infancy, after the first 
bleed and continuing indefinitely (7). This prophylactic 
treatment approach is common in developed countries. 
Indeed chronic synovitis is no longer a problem in 
developed countries (8). Unfortunately prophylactic 
factor concentrate therapy, and on- demand therapy 
are highly expensive, and therefore are not affordable 
by patients in resource poor set ups. Many haemophilia 
patients in these countries eventually develop chronic 
synovitis followed by end stage disabling arthritis. 
Once chronic synovitis has set in, the only way of 
preventing irreversible joint damage is by removal 
of the synovium(9, 10). Synovectomy is therefore 
key to prevention against lifelong disabling arthritis 
in haemophilia patients who have chronic synovitis. 
Synovectomy can be accomplished surgically, or by 
non-surgical procedures (11-13). 
  Radiation synovectomy is not a first line 
treatment for haemarthroses in centres where factor 
concentrates are available and affordable, but rather 
an alternative or supplementary treatment. In the 
developing world where factor concentrates are 
prohibitively expensive, RS has been recommended 
to prevent joint damage. Imaging of the joint with 
MRI or conventional radiography or ultrasonography 
must be undertaken before RS, to establish that the 
joint is not already damaged since patients with 
damaged joints do not benefit from RS (11, 12). 
 
Surgical synovectomy: This is undertaken through 
an open incision, (open synovectomy), or through 
arthroscopy, under general anaesthesia (14,15). Open 
synovectomy requires a major hospital stay and lengthy 
rehabilitation and can cause a loss of joint motion. Large 
amounts of clotting factor concentrates are required 
in haemophiliacs, making the operation extremely 
expensive. Arthroscopic synovectomy requires shorter 
hospitalisation, and may preserve motion but still 
requires massive amounts of prophylactic factor therapy. 
The success rate of surgical synovectomy in controlling 
recurrent bleeds is 80% but the cost is high (11,12). The 
cost of surgical synovectomy in a haemophilia patient 
in the USA has been estimated at US $61,000 (12). 
Chemical synovectomy: Chemicals introduced into a 
joint cavity may cause sclerosis of the synovium. This 
approach has been used with schrosing agents like 
thiotepa, osmic acid, D-pencillaminase, oxytetracycline 
and rifampicin (16,17). These chemicals are readily 
available and relatively inexpensive. Their use however 
is associated with limited clinical success and multiple 
injections are necessary for satisfactory results. Despite 
the use of local anaesthetics, injections of these drugs 
are very painful rendering them unpopular with 
patients (11). 
Radiation synovectomy: Radiation synovectomy, 
radionuclide synovectomy, radio synovectomy, 
radiosynoviorthesis and radioactive synovectomy are 
all terms commonly used to describe synovial ablation 
induced by intra-articular injection of radioisotopes 
(11,12,18). RS transforms richly vascularised synovium 
to sclerotic poorly vascularised tissue that does not bleed 
easily. RS has been in use for treatment of different types 
of arthritis, including rheumatoid arthritis since the early 
1960’s (19). Thousands of patients, including children, 
have undergone RS in many parts of the world to date 
(20-23).Countries where RS treatment of haemophilia 
has been reported include North and South America, 
Europe, Asia, the Far East, South Africa and some North 
African countries (12,23-27). The mid and longterm 
efficacy of RS is 75-80% as measured by decrease, (or 
disappearance), of the number of haem-arthroses (28, 
29). The aim of RS therapy is to prevent arthropathy 
associated with recurrent haemarthrosis and synovitis 
(11, 12). Ideally the RS haemophilia candidate is the 
patient who has recurrent chronic haemarthrosis, but 
who has no, (or has minimum), radiological evidence of 
joint damage. Since RS does not reverse already existing 
damage, RS should be started early in the patient with 
chronic synovitis, (29). Imaging of the target joint is 
recommended before RS for grading of arthropathy 
(30). Magnetic Resonance Imaging (MRI) is more 
sensitive than conventional radiographic studies for 
joint assessment, but in the absence of MRI, combination 
of ultrasonography and conventional radiography has 
proved to be satisfactory (31-33). 
  A successful RS programme requires a well co-
ordinated multidisplinary team of medical specialists 
(11), including musculoskeletal physicians, radiologists, 
nuclear physicians, haematologists, physical therapists 
and appropriately trained nurses (12). The radiologist 
is key in assessing the suitability of the target joint for 
RS. Injection of the radiopharceutical into the joint is 
usually carried out by the musculoskeletal or nuclear 
medicine physician. Physiotherapy and nursing care 
is undertaken by physiotherapists and nurses familiar 
with the care of haemophiliacs. Haematologists co-
ordinates the process and ensures that the coagulation 
factor concentrate is administered before the procedure 
and the desirable level of the coagulation factor is 
achieved to avoid bleeding during the procedure. The 
programme should ideally be located in a designated 
haemophilia treatment centre where there are experts 
in haemophilia management. 
Choice of radioisotopes: Different radiopharmaceuticals 
including Gold, (198Au), (22),32P chromate phosphate, 
(34), Yttrium90, (23), and Dysprosium66, (25), have 
been used for RS. The preferred isotope is one with 
pure beta-emissions, a shallow depth of penetration, 
(to avoid radiation of surrounding tissue), and 
a moderate half life, to allow for gradual energy 
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deposition avoiding immediate inflammatory 
reactions associated with rapidly decaying isotopes 
(35). Yttrium90, (90Y), 32p chromic phosphate, 32p), and 
Dysporosium66 are pure beta- emitters commonly 
used for RS. 32P is the agent of choice in North America, 
while 90Y is  more widely used in Asia; South America, 
Europe and South Africa (11).Leakage of radioisotope 
outside the joint may cause systemic irradiation. To 
avoid leakage the radioisotopes are normally bound 
to a colloid carrier (36). 
Injection procedure: Most centres perform RS as an 
out-patient procedure following a dose of clotting 
factor infusion to a level of around 50%, (11, 12, 24). 
Haemarthrosis is evacuated by arthrocentesis before 
RS following local anaesthetic injection into the joint 
cavity. Intra-articular injection of radioisotopes has been 
described as virtually painless. Rodriguez- Merchan 
(29) has recommended an overnight stay for the few 
patients who may have inhibitors. Echo- graphic guided 
injection has also been recommended, where facilities 
allow, but is not mandatory (12).Addition of steroid 
injections into the joint following the radioisotope 
injection, to reduce post - irradiation inflammatory 
response, is controversial (23). The first injection may 
not be sufficiently effective in 20-25% of patients, and 
a small proportion of patients may require up to three 
injections at 3 -6 monthly intervals (11,12). 
Safety issues: The major safety concern of RS is 
the potential for radiation associated malignancy. 
Chromosomal changes after RS have been studied 
extensively (37). Nonspecific chromosomal changes 
have been described after RS in a small proportion 
of patients following RS with beta emitters but these 
changes disappear within a year of the procedure 
(38). No structural pre-malignant changes have been 
described in these patients. There was concern when 
acute lymphocytic leukaemia (ALL) was described 
in two young haemopihiliacs a few years after they 
underwent RS (39). However when adjusted for the 
expected incidence of ALL in the population, it was 
not clear whether this represented coincidental events 
that occur in accordance with population statistics. 
A long-term follow up of over 5000 patients of patients 
treated with RS did not reveal any radiation induced 
malignancy (28). 
  Other safety concerns are related to local 
radiation effects on the articular cartilage or growth 
plate disturbance in children. The articular cartilage 
has been shown to be very resistant to radiation and 
no damage has been reported in hundreds of children 
who have undergone RS over the last 20 years (12). 
Occasional radiation associated burns along the 
needle tract have been reported but these have healed 
within six weeks (23). Nonetheless strict adherence 
to recommended procedure, and appropriate skill 
for the injection of the radioisotope, is paramount 
to avoid these side effects (10). 
Costs: The cost of RS of a single joint has been estimated 
at US $150 in Spain, andUS $3000 in the United States 
of America (11). The weight of evidence indicates that 
RS is an affordable, minimally invasive procedure 
that is safe, and which greatly improves quality 
of life, by preventing incapacitating crippling end 
arthritis that inevitably follows chronic synovitis. It 
is currently recommended that developing countries 
should adopt RS for a healthier future generation of 
haemophilia patients. 
CONCLUSION 
In Kenya there are many patients afflicted by 
haemophilia and allied bleeding disorders (40). Many 
have severe haemophilia or Christmas disease and are 
frequently admitted for management of haemarthrosis. 
Clotting factor concentrates are unaffordable to the 
majority of patients in public health facilities for 
prophylactic treatment or on demand treatment 
of bleeds (41). Although small quantities of factor 
replacement concentrates are availed by donors from 
time to time in the public health facilities, the supplies 
are too few and erratic. The main treatment choices 
available for the management of these patients are 
cryoprecipitates or fresh frozen plasma, (FFP), often 
in combination with antifibrinolytic drugs. These 
products do not contain sufficient coangulation factors 
for adequate and effective treatment of haemarthrosis. 
Many of the patients therefore end up with incomplete 
resolution of haemarthrosis and eventually develop 
chronic synovitis and subsequent end stage 
haemophilic arthropathy. For the significant number 
of patients who currently have chronic synovitis, there 
is an urgent need to consider the treatment option of 
RS to spare them from disabling end stage arthritis. 
Since the procedure of RS requires very little factor 
concentrates, some of the donated concentrates could 
be used to cover these procedures. 
  Kenya is well endowed with the necessary cadres 
of professional specialists for an RS programme. Most 
are familiar with the care of haemophilia care and only 
minimal further training would be required to start 
an RS programme in Kenya. RS would also reduce 
the risk of transmission of blood borne transmissible 
infections associated with repeated blood and blood 
products transfusion, in haemophilic patients. 
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